A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.

导出 OA

翻译打印收藏纠错

第一作者： Xiao-Fang,Guo

第一单位： Department of Microbiology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China.

作者： Xiao-Fang,Guo ^[1] ; Xiao-Fei,Zhu ^[2] ; Hai-Ying,Cao ^[3] ; Gen-Shen,Zhong ^[1] ; Liang,Li ^[4] ; Bao-Guo,Deng ^[5] ; Ping,Chen ^[1] ; Pei-Zhen,Wang ^[1] ; Qing-Fang,Miao ^[1] ; Yong-Su,Zhen ^[5]

作者单位： Department of Microbiology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China. ^[1] Department of Clinical Immunology, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, China. ^[2] Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, Xinxiang, China. ^[3] Laboratory of Cancer Biotherapy, Institute of Neurology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China. ^[4] Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Perking Union Medical College, Beijing, China. ^[5]

关键词 EGFR IGF-1R NSCLC bispecific fusion protein lidamycin